Global SERD Therapeutics Market - 1-3 USERS:2021

Market Report Coverage :
Start Year : 2020 - Forecast Year : 2030 - Start Value : $874.9 Million in 2020 - Forecast Value : $4,085.0 Million by 2030 - CAGR % : 0.17%
Description :
Market Report Coverage - SERD TherapeuticsMarket Segmentation• By Product – Faslodex, RAD1901, GDC-9545, AZD9833, SAR439859, Other Generics• By Application – First-line treatment and second-line treatmentRegional Segmentation• North America – U.S., Canada• Europe – Germany, France, U.K., Italy, Spain, and Rest-of-Europe• Asia-Pacific – China, Japan, and Rest-of-Asia-Pacific (RoAPAC)• Rest-of-the-WorldGrowth Drivers• Rising incidence of breast cancer• Advanced route of administration: oral drug deliveryMarket Challenges• Resistance to endocrine therapyMarket Opportunities• SERDs as combination therapy• Therapeutic potential in different types of cancerKey Companies ProfiledAstraZeneca, Plc, Novartis AG, Sanofi S.A, Hofmann-la Roche AG, G1 Therapeutics, Zentalis Pharmaceuticals, Zenopharm LLC, Radius Health, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd, InventisBio, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, HBT Labs, and Amneal pharmaceuticals, Inc.Key Questions Answered in this Report:• What is SERD therapy?• How did the SERD therapy market evolve, and what is its scope in the future?• What are the major market drivers, restraints, and opportunities in the global SERD therapeutics market?• What are the key developmental strategies that are being implemented by the key players to sustain this market?• What is the impact of generics on branded therapy? • What is the impact of COVID-19 on this market?• What are the guidelines implemented by different government bodies to regulate the approval of products to be used in breast cancer treatment? • How is SERD therapy being utilized for the treatment of postmenopausal women with breast cancer?• What was the market size of the leading segments and sub-segments of the global SERD therapeutics market in 2019?• How will the industry evolve during the forecast period 2020-2030?• What will be the growth rate of the SERD therapeutics market during the forecast period?• How will each segment of the global SERD therapeutics market grow during the forecast period, and what will be the revenue generated by each segment by the end of 2030?• Which product segment and application segment are expected to register the highest CAGR for the global SERD therapeutics market?• What is the market size of the SERD therapeutics market in different countries of the world?• Which geographical region is expected to contribute to the highest sales in the global SERD therapeutics market?• What is the regulatory framework for the SERD therapeutics market in different regions?• What are the key strategies incorporated by the players of the global SERD therapeutics market to sustain the competition and retain their supremacy?Market OverviewThe unmet clinical benefits and quest for novel therapies with better efficacy and safety to improve the quality of life in patients living with breast cancer treatment, complete estrogen receptor inhibition, and resistance to multiple endocrine therapies led to the discovery of SERD therapies. SERD therapy has been extensively accepted and used as both monotherapy and in combination with other therapeutic agents. The potential of SERD therapy in breast cancer treatment is yet to be fully discovered, thus leaving a substantial scope of innovation and research in the field.The global SERD therapeutics market was valued at $1000.2 million in 2019 and is expected to reach $4085.0 million by 2030, witnessing a CAGR of 16.66% during the forecast period 2020-2030. The market growth can mainly be attributed to the increasing breast cancer incidence and mortality worldwide, increasing number of relapsed or refractory cases in breast cancer, unmet clinical benefits with existing breast cancer treatments targeting hormone receptor-positive metastatic breast cancer, eased route of administration and dosage exposure, rising focus of the key players on research and development (R&D) activity for new product launch, and increased government and private funding for improved safety and outcomes provided by SERD therapy.The global SERD therapeutics market is expected to witness high growth in the future. The increasing global breast cancer incidence and mortality and increased demand for endocrine therapies that cure chronic conditions completely and improve the quality of life of patients are the major factors anticipated to contribute to the growth of the global SERD therapeutics market.Furthermore, the increasing number of relapsed or refractory cases in breast cancer, unmet clinical benefits with existing breast cancer treatments targeting hormone receptor-positive metastatic breast cancer, painful route of administration and limited dosage exposure will augment the SERD therapeutics market. Also, the increased use of SERDs as combination therapy with other endocrine agents and rising focus of the key players on research and development (R&D) activity for new product launch is expected to drive the market. Rise in government and private funding for improved safety and outcomes provided by SERD therapy are additional factors propelling the growth.Within the research report, the market is segmented based on therapy type, product, region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe global SERD therapeutics market is currently dominated by Sandoz, Mylan N.V., Glenmark Pharmaceuticals, Dr. Reddy’s Laboratories, Accord Healthcare, and Teva Pharmaceuticals Industries Ltd. The market dominance of these companies can be attributed to cost-effective generic fulvestrant availability in the market. As of 2018, AstraZeneca Plc was the only company to offer SERD therapy in the global SERD therapeutics market. The company has now witnessed a sharp decline after generic launch in several regions. With the pipeline of SERD therapeutics, the market is expected to augment tremendously. Some of the major companies with strong and early pipeline include Sanofi S.A., Hoffmann-La Roche AG, Radius Health, and AstraZeneca Plc.Based on region, North America is the leading contributor to the SERD therapeutics market in terms of revenue. The growing breast cancer incidence, relapse from existing endocrine therapies, and the substantial research and development made in the field are consequentially promoting the growth of the North America SERD therapeutics market. Also, the Asia-Pacific and Europe regions are expected to register the high CAGR during the forecast period of 2020-2030.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France Spain U.K. Rest-of-EuropeAsia-Pacific China Japan Rest-of-Asia-PacificRest-of-World
Keywords :
SERD Therapeutics, SERD, Selective estrogen receptor degrader Therapeutics, Selective estrogen receptor degrader, SERD Therapeutics Market, SERD Therapeutics Report, SERD Therapeutics Industry, SERD Therapeutics Market Forecast, SERD Therapeutics Trends, SERD Therapeutics Products, SERD Therapeutics Applications, SERD Therapeutics Technology, SERD Therapeutics Companies, SERD Therapeutics Market Analysis, SERD Therapeutics Industry Analysis, What is SERD Therapeutics Market, What are SERD Therapeutics Market, SERD Therapeutics Market by Therapy, SERD Therapeutics Market by Product, SERD Therapeutics Market by Region, North America SERD Therapeutics Market, Europe SERD Therapeutics Market, Asia-Pacific SERD Therapeutics Market
Press Release :
The global SERD therapeutics market is projected to reach $4.0 billion by 2030, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 16.66% between 2020 and 2030.In the comprehensive study of the global SERD therapeutics market, BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market• Clinical trial analysis• Commercialized and pipeline therapies• Role of SERDs in breast cancer treatment • Impact of novel drugs on available therapies• Branded and generic drug dosages and sale insight• Market share analysis• Breast Cancer epidemiology • Growth analysis by therapy, product, and region• Company and product profiling for 15 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, and segmental analysis.BIS Research study indicates that the increasing global breast cancer incidence and mortality, and increased demand for endocrine therapies, that not only cure the chronic conditions completely but also improve the quality of life of the patients are the major factors anticipated to contribute to the growth of the global SERD therapeutics market.BIS Research study highlights the following in the report:• Emerging opportunities of SERD therapeutics• Pipeline therapies’ design and potential in breast cancer• Increase in research and development of novel therapies in breast cancer treatment• The massive scope for adoption of SERD therapy as monotherapy in postmenopausal women with breast cancer and other different types of cancer• Strategic collaborations in pharmaceutical industries, and clinical trial landscape.Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include market segmented on the basis of product, application, end user, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.To emphasize the dominance of SERD therapeutics market in breast cancer treatment in 2019 and 2030, Sara Virmani, Research Analyst – BIS Research, states, "The reason for market growth and the dominance of SERD therapeutics can be attributed to the increasing breast cancer incidence and mortality worldwide, increasing number of relapsed or refractory cases in breast cancer, unmet clinical benefits with existing breast cancer treatments targeting hormone receptor-positive metastatic breast cancer, painful route of administration and limited dosage exposure. The rising focus of the key players on research and development (R&D) activity for new product launch, and increased government and private funding for improved safety and outcomes provided by SERD therapy. Also, the increased use of SERDs as combination therapy with other endocrine agents is expected to augment the market.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The key players operating in the global SERD therapeutics market include AstraZeneca, Plc, Novartis AG, Sanofi S.A, Hofmann-la Roche AG, G1 Therapeutics, Zentalis Pharmaceuticals, Zenopharm LLC, Radius Health, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd, InventisBio, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, HBT Labs, and Amneal Pharmaceuticals, Inc.The study also offers strategic recommendations that can help organizations in tracking various pipeline products, trends, and opportunities that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers of endocrine therapies• Distributors of endocrine therapies• Suppliers of endocrine therapies• CROs of endocrine therapies• Research, hospitals, and academic institutions How can market intelligence on SERD therapeutics add value to an organization’s decision-making process?• Aid in product development • Aid in analyzing the pipeline of products• Help in targeting a segment for launching a new product • Offer go-to market strategies for the different product categories• Support in diversifying the product portfolio based on unmet needs• Help in analyzing technological substitutes and compare the specification• Help in understanding the clinical trial landscape.• Help to adjust the pricing of upcoming products• Assist in exploring the newer applications• Support in analyzing the competitors’ funding scenarioInsightful Questions Covered to Enable Companies Take Strategic Decisions• What is SERD therapy?• How did the SERD therapy market evolve, and what is its scope in the future?• What are the major market drivers, restraints, and opportunities in the global SERD therapeutics market?• What are the key developmental strategies that are being implemented by the key players to sustain this market?• What is the impact of generics on branded therapy? • What is the impact of COVID-19 on this market?• What are the guidelines implemented by different government bodies to regulate the approval of products to be used in breast cancer treatment? • How is SERD therapy being utilized for the treatment of postmenopausal women with breast cancer?• What was the market size of the leading segments and sub-segments of the global SERD therapeutics market in 2019?• How will the industry evolve during the forecast period 2020-2030?• What will be the growth rate of the SERD therapeutics market during the forecast period?• How will each segment of the global SERD therapeutics market grow during the forecast period, and what will be the revenue generated by each segment by the end of 2030?• Which product segment and application segment are expected to register the highest CAGR for the global SERD therapeutics market?• What is the market size of the SERD therapeutics market in different countries of the world?• Which geographical region is expected to contribute to the highest sales in the global SERD therapeutics market?• What is the regulatory framework for the SERD therapeutics market in different regions?• What are the key strategies incorporated by the players of the global SERD therapeutics market to sustain the competition and retain their supremacy?
Companies Mentioned :
Amneal Pharmaceuticals IncAstraZeneca, PlcDr. Reddy’s LaboratoriesEli Lilly and CompanyG1 Therapeutics, Inc.Glenmark PharmaceuticalsHBT Labs, IncHoffmann-La Roche AGInventisBioNovartis AGRadius HealthSanofi S.A.Teva Pharmaceutical Industries Ltd.Zenopharm LLCZentalis Pharmaceuticals
Press Release :
The global SERD therapeutics market is projected to reach $4.0 billion by 2030, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 16.66% between 2020 and 2030.In the comprehensive study of the global SERD therapeutics market, BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market• Clinical trial analysis• Commercialized and pipeline therapies• Role of SERDs in breast cancer treatment • Impact of novel drugs on available therapies• Branded and generic drug dosages and sale insight• Market share analysis• Breast Cancer epidemiology • Growth analysis by therapy, product, and region• Company and product profiling for 15 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, and segmental analysis.BIS Research study indicates that the increasing global breast cancer incidence and mortality, and increased demand for endocrine therapies, that not only cure the chronic conditions completely but also improve the quality of life of the patients are the major factors anticipated to contribute to the growth of the global SERD therapeutics market.BIS Research study highlights the following in the report:• Emerging opportunities of SERD therapeutics• Pipeline therapies’ design and potential in breast cancer• Increase in research and development of novel therapies in breast cancer treatment• The massive scope for adoption of SERD therapy as monotherapy in postmenopausal women with breast cancer and other different types of cancer• Strategic collaborations in pharmaceutical industries, and clinical trial landscape.Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include market segmented on the basis of product, application, end user, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.To emphasize the dominance of SERD therapeutics market in breast cancer treatment in 2019 and 2030, Sara Virmani, Research Analyst – BIS Research, states, "The reason for market growth and the dominance of SERD therapeutics can be attributed to the increasing breast cancer incidence and mortality worldwide, increasing number of relapsed or refractory cases in breast cancer, unmet clinical benefits with existing breast cancer treatments targeting hormone receptor-positive metastatic breast cancer, painful route of administration and limited dosage exposure. The rising focus of the key players on research and development (R&D) activity for new product launch, and increased government and private funding for improved safety and outcomes provided by SERD therapy. Also, the increased use of SERDs as combination therapy with other endocrine agents is expected to augment the market.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The key players operating in the global SERD therapeutics market include AstraZeneca, Plc, Novartis AG, Sanofi S.A, Hofmann-la Roche AG, G1 Therapeutics, Zentalis Pharmaceuticals, Zenopharm LLC, Radius Health, Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd, InventisBio, Dr. Reddy’s Laboratories, Glenmark Pharmaceuticals, HBT Labs, and Amneal Pharmaceuticals, Inc.The study also offers strategic recommendations that can help organizations in tracking various pipeline products, trends, and opportunities that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers of endocrine therapies• Distributors of endocrine therapies• Suppliers of endocrine therapies• CROs of endocrine therapies• Research, hospitals, and academic institutions How can market intelligence on SERD therapeutics add value to an organization’s decision-making process?• Aid in product development • Aid in analyzing the pipeline of products• Help in targeting a segment for launching a new product • Offer go-to market strategies for the different product categories• Support in diversifying the product portfolio based on unmet needs• Help in analyzing technological substitutes and compare the specification• Help in understanding the clinical trial landscape.• Help to adjust the pricing of upcoming products• Assist in exploring the newer applications• Support in analyzing the competitors’ funding scenarioInsightful Questions Covered to Enable Companies Take Strategic Decisions• What is SERD therapy?• How did the SERD therapy market evolve, and what is its scope in the future?• What are the major market drivers, restraints, and opportunities in the global SERD therapeutics market?• What are the key developmental strategies that are being implemented by the key players to sustain this market?• What is the impact of generics on branded therapy? • What is the impact of COVID-19 on this market?• What are the guidelines implemented by different government bodies to regulate the approval of products to be used in breast cancer treatment? • How is SERD therapy being utilized for the treatment of postmenopausal women with breast cancer?• What was the market size of the leading segments and sub-segments of the global SERD therapeutics market in 2019?• How will the industry evolve during the forecast period 2020-2030?• What will be the growth rate of the SERD therapeutics market during the forecast period?• How will each segment of the global SERD therapeutics market grow during the forecast period, and what will be the revenue generated by each segment by the end of 2030?• Which product segment and application segment are expected to register the highest CAGR for the global SERD therapeutics market?• What is the market size of the SERD therapeutics market in different countries of the world?• Which geographical region is expected to contribute to the highest sales in the global SERD therapeutics market?• What is the regulatory framework for the SERD therapeutics market in different regions?• What are the key strategies incorporated by the players of the global SERD therapeutics market to sustain the competition and retain their supremacy?
Headline :
Global SERD Therapeutics Market to Reach $4.0 Billion by 2030
Table of Contents :
Executive Summary 1 Definition1.1 Inclusion and Exclusion Criteria2 Research Scope2.1 Target Audience2.2 Key Questions Answered in the Report3 Research Methodology3.1 SERD Therapeutics: Research Methodology3.2 Primary Data Sources3.3 Secondary Data Sources3.4 Market Estimation Model3.5 Criteria for Company Profiling4 Market Overview4.1 Definition4.2 Progression in SERD Therapeutics4.3 SERD Therapeutics: Mechanism of Action4.4 SERD Therapeutics: Forms of Administration4.5 SERD Therapeutics Market and Growth Potential, 2019-20304.6 Impact of Novel Drugs on Available Therapies5 Epidemiology of Breast Cancer5.1 Overview5.2 Breast Cancer Classification5.2.1 Types of Breast Cancer5.2.2 Molecular Subtypes of Breast Cancer5.2.3 Stages of Breast Cancer5.2.4 Population (Premenopausal and Postmenopausal)5.2.5 Breast Cancer Incidence and Mortality (by Region), 20205.2.6 Role of Molecular Biomarkers in Breast Cancer Treatment5.3 SERDs in Breast Cancer Treatment5.4 Breast Cancer in Male6 SERD Therapeutics Clinical Trials Landscape6.1 Overview6.2 SERD Therapeutics Clinical Trials Current Scenario7 Impact of COVID-19 on SERD Therapeutics7.1.1 Impact of COVID-19 on Breast Cancer Treatment7.1.2 Impact of COVID-19 on Global SERD Therapeutics Market Growth Rate7.1.3 Clinical Trial Disruptions and Resumptions8 Global SERD Commercialized and Pipeline Therapeutics8.1 Commercialized Therapeutics8.2 Faslodex Overview8.3 Faslodex Pricing and Reimbursement Scenario8.3.1 Faslodex Sales Analysis8.3.2 Generic Fulvestrant Overview8.3.2.1 Impact of Generic Fulvestrant on Faslodex Global Revenue8.4 Pipeline Therapeutics9 Industry Insights9.1 Overview9.2 Regulatory Scenario of Endocrine Therapy9.3 Legal Requirements and Frameworks in the U.S.9.3.1 Clinical Trial Authorization9.3.2 Marketing Authorization9.3.3 USFDA Guidelines for NDA Submission9.3.4 Post-Authorization Regulations9.4 Legal Requirements and Frameworks in Europe9.4.1 Centralized Procedure9.4.2 Decentralized Procedure9.4.3 Mutual-Recognition Procedure9.4.4 National Procedure9.5 Legal Requirements and Frameworks in Asia-Pacific9.5.1 Legal Requirements and Frameworks in China9.5.2 Legal Requirements and Frameworks in Japan9.6 Expedited Regulatory Designations Around the World10 Market Dynamics10.1 Impact Analysis10.2 Market Drivers10.2.1 Rising Incidence of Breast Cancer10.2.2 Advanced Route of Administration: Oral Drug Delivery10.3 Market Restraints10.3.1 Resistance to Endocrine Therapy10.4 Market Opportunities10.4.1 SERDs as Combination Therapy10.4.2 Therapeutic Potential in Different Types of Cancers11 Global SERD Therapeutics Market (by Therapy)11.1 Overview11.2 First-Line Treatment11.3 Second-Line Treatment12 Global SERD Therapeutics Market (by Product)12.1 Overview12.2 Faslodex12.3 RAD190112.4 GDC-954512.5 AZD983312.6 SAR43985912.7 Other Generics13 Global SERD Therapeutics Market (by Region)13.1 North America13.1.1 U.S.13.1.2 Canada13.2 Europe13.2.1 U.K.13.2.2 Germany13.2.3 France13.2.4 Italy13.2.5 Spain13.2.6 Rest-of-Europe13.3 Asia-Pacific13.3.1 China13.3.2 Japan13.3.3 Rest-of-APAC13.4 Rest-of-the-World14 Competitive Landscape14.1 Key Developments and Strategies14.1.1 Regulatory and Legal Developments14.1.1.1 Synergistic Activities14.1.1.2 Mergers and Acquisitions (M&A) Activities14.1.1.3 Funding and Business Strategy Activities14.2 Market Share Analysis15 Company Profiles15.1 Overview15.2 Amneal Pharmaceuticals Inc 15.2.1 Company Overview 15.2.2 Role of Amneal Pharmaceuticals Inc in the Global SERD Therapeutics Market 15.2.3 Financials 15.2.4 R&D Expenditure, 2017-2019 15.2.5 SWOT Analysis15.3 AstraZeneca, Plc. 15.3.1 Company Overview 15.3.2 Role of AstraZeneca, Plc. in the Global SERD Therapeutics Market 15.3.3 Financials 15.3.4 R&D Expenditure, 2017-2019 15.3.5 SWOT Analysis15.4 Dr. Reddy’s Laboratories 15.4.1 Company Overview 15.4.2 Role of Dr. Reddy’s Laboratories in the Global SERD Therapeutics Market 15.4.3 Financials 15.4.4 R&D Expenditure, 2017-2019 15.4.5 SWOT Analysis15.5 Eli Lilly and Company 15.5.1 Company Overview 15.5.2 Role of Eli Lilly and Company in the Global SERD Therapeutics Market 15.5.3 Financials 15.5.4 R&D Expenditure, 2017-2019 15.5.5 SWOT Analysis15.6 G1 Therapeutics, Inc. 15.6.1 Company Overview 15.6.2 Role of G1 Therapeutics, Inc. in the Global SERD Therapeutics Market 15.6.3 Financials 15.6.4 R&D Expenditure, 2017-2019 15.6.5 SWOT Analysis15.7 Glenmark Pharmaceuticals 15.7.1 Company Overview 15.7.2 Role of Glenmark Pharmaceuticals in the Global SERD Therapeutics Market 15.7.3 Financials 15.7.4 R&D Expenditure, 2017-2019 15.7.5 SWOT Analysis15.8 HBT Labs, Inc 15.8.1 Company Overview 15.8.2 Role of HBT Labs, Inc in the Global SERD Therapeutics Market 15.8.3 SWOT Analysis15.9 Hoffmann-La Roche AG 15.9.1 Company Overview 15.9.2 Role of Hoffmann-La Roche AG in the Global SERD Therapeutics Market 15.9.3 Financials 15.9.4 R&D Expenditure, 2017-2019 15.9.5 SWOT Analysis15.10 InventisBio 15.10.1 Company Overview 15.10.2 Role of InventisBio in the Global SERD Therapeutics Market 15.10.3 SWOT Analysis15.11 Novartis AG 15.11.1 Company Overview 15.11.2 Role of Novartis AG in the Global SERD Therapeutics Market 15.11.3 Financials 15.11.4 R&D Expenditure, 2017-2019 15.11.5 SWOT Analysis15.12 Radius Health 15.12.1 Company Overview 15.12.2 Financials 15.12.3 R&D Expenditure, 2017-2019 15.12.4 SWOT Analysis15.13 Sanofi S.A. 15.13.1 Company Overview 15.13.2 Financials 15.13.3 R&D Expenditure, 2017-2019 15.13.4 SWOT Analysis15.14 Teva Pharmaceutical Industries Ltd. 15.14.1 Company Overview 15.14.2 Role of Teva Pharmaceutical Industries Ltd. in the SERD Therapeutics Market 15.14.3 Financials 15.14.4 R&D Expenditure, 2017-2019 15.14.5 SWOT Analysis15.15 Zenopharm LLC. 15.15.1 Company Overview 15.15.2 Role of Zenopharm LLC in the Global SERD Therapeutics Market 15.15.3 SWOT Analysis15.16 Zentalis Pharmaceuticals 15.16.1 Company Overview 15.16.2 Role of Zentalis Pharmaceuticals in the Global SERD Therapeutics Market 15.16.3 Financials 15.16.4 R&D Expenditure, 2017-2019 15.16.5 SWOT AnalysisList of Tables Table 1: Leading Players in Global SERD Therapeutics MarketTable 4.1: Available Novel Therapies in Breast CancerTable 6.1: SERDs Undergoing Clinical Development and Trial DesignTable 7.1: Impact of COVID-19 on SERDs Clinical TrialsTable 8.1: Generic Fulvestrant Approvals by USFDA, 2019-2020Table 9.2: Expedited Regulatory Designations Around the WorldTable 15.1: AstraZeneca Plc: Pipeline Product PortfolioTable 15.2: Eli Lilly and Company: Pipeline Product PortfolioTable 15.3: G1 Therapeutics, Inc.: Pipeline Product PortfolioTable 15.4: Hoffmann-La Roche AG: Pipeline Product PortfolioTable 15.5: InventisBio: Pipeline Product PortfolioTable 15.6: Novartis AG: Pipeline Product PortfolioTable 15.7: Radius Health: Pipeline Product PortfolioTable 15.8: Sanofi S.A.: Pipeline Product PortfolioTable 15.9: Zenopharm LLC: Pipeline Product PortfolioTable 15.10: Zentalis Pharmaceutical.: Pipeline Product PortfolioList of Figures Figure 1: Top Five Cancers with the Highest Incidence, 2020Figure 2: Leading Mortality Cancers, 2020Figure 3: Global SERD Therapeutics Clinical Trials (by Phase)Figure 4: Global SERD Therapeutics Market, $Million, 2019-2030Figure 5: Global SERD Therapeutics: Impact AnalysisFigure 6: Share of Key Developments and Strategies, January 2017-December 2020Figure 7: Global SERD Therapeutics Market (by Therapy), 2019 and 2030Figure 8: Global SERD Therapeutics Market (by Product)Figure 9: Global SERD Therapeutics Market (by Region), 2019 and 2030Figure 2.1: Global SERD Therapeutics Market SegmentationFigure 3.1: Global SERD Therapeutics Market MethodologyFigure 3.2: Primary Research MethodologyFigure 3.3: Bottom-Up Approach (Segment-Wise Analysis)Figure 3.4: Top-Down Approach (Segment-Wise Analysis)Figure 4.1: Chemical Classes of SERDsFigure 4.2: SERD Therapeutics DevelopmentFigure 4.3: SERDs Mechanism of ActionFigure 4.4: SERDs Route of AdministrationFigure 4.5: SERD Therapeutics Market Growth Revenue, 2019-2030Figure 5.1: Breast Cancer Types and SubtypesFigure 5.2: Most Common Types of Breast CancerFigure 5.3: Female Breast Cancer Cases (by Subtype), U.S., 2013-2017Figure 5.4: Breast Cancer Classification (by Stage)Figure 5.5: Global Premenopausal and Postmenopausal Breast Cancer ASIR, 2018Figure 5.6: Female Breast Cancer New Cases (by Age Group), U.S., 2012-2016Figure 5.7: Geographies with the Highest ASIR for Female Breast Cancer, 2020Figure 5.8: Geographies with the Highest Age-Standardized Mortality Rate for Female Breast Cancer, 2020Figure 5.9: Few Categories of Molecular Biomarkers in Breast CancerFigure 5.10: Male Breast Cancer Risk FactorsFigure 6.1: SERD Therapeutics Global Clinical Trials (by Phase), 2020Figure 7.1: Estimated Overall Excess Deaths from Breast Cancers in the U.S. Due to COVID-19, 2020-2030Figure 7.2: COVID-19 Impact on SERD Therapeutics MarketFigure 7.3: Impact of COVID-19 on Clinical TrialsFigure 8.1: Faslodex FDA Approval Timeline in the U.S.Figure 8.2: Faslodex Treatment Dosing RegimenFigure 8.3: Faslodex Global Revenue, 2015-2018Figure 8.4: Geography-Specific Faslodex Revenue, 2015-2018Figure 8.5: Impact of Generic Fulvestrant on Global Sales of Faslodex, 2018-2020Figure 8.6: Dose Regimen of Some Oral SERDs in PipelineFigure 9.1: Clinical Trial Authorization for Endocrine Therapy in the U.S.Figure 9.2: Steps for Obtaining Marketing AuthorizationFigure 9.3: USFDA Review TimelineFigure 9.4: EMA Drug License Application Process and Review TimelineFigure 10.1: Global SERD Therapeutics Market: Impact AnalysisFigure 10.2: Estimated Incidence of Breast Cancer Worldwide, 2020-2040Figure 10.3: Risk Factors Related to Breast CancerFigure 10.4: Potential Resistance Mechanisms to Endocrine TherapyFigure 10.5: SERDs in Combination with Other Therapeutic AgentsFigure 10.6: SERDs Potential in Different Types of CancersFigure 11.1: Revenue Contribution of Global SERD Therapeutics Market (by Therapy), $Million, 2019 and 2030Figure 11.2: Global SERD Therapeutics Market (First-Line Treatment), $Million, 2019-2030Figure 11.3: Global SERD Therapeutics Market (Second-Line Treatment), $Million, 2019-2030Figure 12.1: Global SERD Therapeutics Market (by Product), $Million, 2019 and 2030Figure 12.2: Global SERD Therapeutics Market (Faslodex), $Million, 2019-2030Figure 12.3: Global SERD Therapeutics Market (RAD1901), $Million, 2019-2030Figure 12.4: Global SERD Therapeutics Market (GDC-9545), $Million, 2019-2030Figure 12.5: Global SERD Therapeutics Market (AZD9833), $Million, 2019-2030Figure 12.6: Global SERD Therapeutics Market (SAR439859), $Million, 2019-2030Figure 12.7: Global SERD Therapeutics Market (Other Generics), $Million, 2019-2030Figure 13.1: Global SERD Therapeutics Market (by Region)Figure 13.2: Global SERD Therapeutics Market (by Region), 2019 and 2030Figure 13.3: North America SERD Therapeutics Market, $Million, 2019-2030Figure 13.4: North America: Market DynamicsFigure 13.5: Revenue Contribution of Various Countries in North America, $Million, 2019 and 2030Figure 13.6: U.S. SERD Therapeutics Market, $Million, 2019-2030Figure 13.7: Canada SERD Therapeutics Market, $Million, 2019-2030Figure 13.8: Europe SERD Therapeutics Market, $Million, 2019-2030Figure 13.9: Europe: Market DynamicsFigure 13.10: Revenue Contribution of Various Countries in Europe, $Million, 2019 and 2030Figure 13.11: U.K. SERD Therapeutics Market, $Million, 2019-2030Figure 13.12: Germany SERD Therapeutics Market, $Million, 2019-2030Figure 13.13: France SERD Therapeutics Market, $Million, 2019-2030Figure 13.14: Italy SERD Therapeutics Market, $Million, 2019-2030Figure 13.15: Spain SERD Therapeutics Market, $Million, 2019-2030Figure 13.16: Rest-of-Europe SERD Therapeutics Market, $Million, 2019-2030Figure 13.17: Asia-Pacific SERD Therapeutics Market, $Million, 2019-2030Figure 13.18: Asia-Pacific: Market DynamicsFigure 13.19: Revenue Contributions of Various Countries in Asia-Pacific, $Million, 2019 and 2030Figure 13.20: China SERD Therapeutics Market, $Million, 2019-2030Figure 13.21: Japan SERD Therapeutics Market, $Million, 2019-2030Figure 13.22: Rest-of-APAC SERD Therapeutics Market, $Million, 2019-2030Figure 13.23: RoW SERD Therapeutics market, $Million, 2019-2030Figure 14.1: Share of Key Developments and Strategies, January 2017-December 2020Figure 14.2: Regulatory and Legal Developments Share (by Company), January 2017 – December 2020Figure 14.3: Synergistic Activities (by Company), January 2017 - December 2020Figure 14.4: Funding and Business Strategy Activities (by Company), January 2017-December 2020Figure 14.5: Market Share Analysis (by Company), 2018 and 2019Figure 15.1: Total Number of Companies ProfiledFigure 15.2: Amneal Pharmaceuticals Inc: Overall Financials, 2017-2019Figure 15.3: Amneal Pharmaceuticals Inc: Sales (by Business Segment), 2017-2019Figure 15.4: Amneal Pharmaceuticals Inc. Revenue (by Region), 2017-2019Figure 15.5: Amneal Pharmaceuticals Inc.: R&D Expenditure, 2017-2019Figure 15.6: Amneal Pharmaceuticals, Inc: SWOT AnalysisFigure 15.7: AstraZeneca, Plc.: Overall Financials, 2017-2019Figure 15.8: AstraZeneca, Plc.: Sales (by Business Segment), 2017-2019Figure 15.9: AstraZeneca, Plc.: Revenue (by Region), 2017-2019Figure 15.10: AstraZeneca, Plc.: R&D Expenditure, 2017-2019Figure 15.11: AstraZeneca, Plc.: SWOT AnalysisFigure 15.12: Dr. Reddy’s Laboratories: Overall Financials, 2017-2019Figure 15.13: Dr. Reddy’s Laboratories: Sales (by Business Segment), 2017-2019Figure 15.14: Dr. Reddy’s Laboratories: Revenue (by Region), 2017-2019Figure 15.15: Dr. Reddy’s Laboratories: R&D Expenditure, 2017-2019Figure 15.16: Dr. Reddy’s Laboratories: SWOT AnalysisFigure 15.17: Eli Lilly and Company: Overall Financials, 2017-2019Figure 15.18: Eli Lilly and Company: Sales (by Business Segment), 2017-2019Figure 15.19: Eli Lilly and Company: Revenue (by Region), 2017-2019Figure 15.20: Eli Lilly and Company: R&D Expenditure, 2017-2019Figure 15.21: Eli Lilly and Company: SWOT AnalysisFigure 15.22: G1 Therapeutics, Inc. Overall Financials, 2017-2019Figure 15.23: G1 Therapeutics, Inc.: Clinical Expenses (by Product), 2017-2019Figure 15.24: G1 Therapeutics, Inc.: R&D Expenditure, 2017-2019Figure 15.25: G1 Therapeutics, Inc.: SWOT AnalysisFigure 15.26: Glenmark Pharmaceuticals: Overall Financials, 2017-2019Figure 15.27: Glenmark Pharmaceuticals: Revenue (by Region), 2017-2019Figure 15.28: Glenmark Pharmaceuticals: R&D Expenditure, 2017-2019Figure 15.29: Glenmark Pharmaceuticals: SWOT AnalysisFigure 15.30: HBT Labs, Inc: SWOT AnalysisFigure 15.31: Hoffmann-La Roche AG: Overall Financials, 2017-2019Figure 15.32: Hoffmann-La Roche AG: Revenue (by Business Segment), 2017-2019Figure 15.33: Hoffmann-La Roche AG: Revenue (by Region), 2017-2019Figure 15.34: Hoffmann-La Roche AG: R&D Expenditure, 2017-2019Figure 15.35: Hoffmann-La Roche AG: SWOT AnalysisFigure 15.36: InventisBio: SWOT AnalysisFigure 15.37: Novartis AG: Overall Financials, 2017-2019Figure 15.38: Novartis AG Net Revenue (by Business Segment), 2017-2019Figure 15.39: Novartis AG: Net Revenue (by Region), 2017-2019Figure 15.40: Novartis AG: R&D Expenditure, 2017-2019Figure 15.41: Novartis AG: SWOT AnalysisFigure 15.42: Radius Health: Overall Financials, 2017-2019Figure 15.43: Radius Health: Product Specific R&D Expenditure, 2017-2019Figure 15.44: Radius Health: R&D Expenditure, 2017-2019Figure 15.45: Radius Health: SWOT AnalysisFigure 15.46: Sanofi S.A.: Overall Financials, 2017-2019Figure 15.47: Sanofi S.A. Net Revenue (by Business Segment), 2017-2019Figure 15.48: Sanofi S.A.: Net Revenue (by Region), 2017-2019Figure 15.49: Sanofi S.A.: R&D Expenditure, 2017-2019Figure 15.50: Sanofi S.A.: SWOT AnalysisFigure 15.51: Teva Pharmaceutical Industries Ltd.: Overall Financials, 2017-2019Figure 15.52: Teva Pharmaceutical Industries Ltd.: Net Revenue (by Business Segment), 2017-2019Figure 15.53: Teva Pharmaceutical Industries Ltd.: Research and Development Expenditure, 2017-2019Figure 15.54: Teva Pharmaceutical Industries Ltd.: SWOT AnalysisFigure 15.55: Zenopharm LLC: SWOT AnalysisFigure 15.56: Zentalis Pharmaceuticals: Overall Financials, 2017-2019Figure 15.57: Zentalis Pharmaceuticals: Product-Specific R&D Expenditure, 2017-2019Figure 15.58: Zentalis Pharmaceuticals: R&D Expenditure, 2017-2019Figure 15.59: Zentalis Pharmaceuticals: SWOT Analysis